The Lupus Research Alliance is the world’s largest nongovernment funder of lupus research, with 100% of donations going to research programs because our Board of Directors funds all administrative and fundraising costs. The following is an overview of the Lupus Research Alliance’s income and expenditures for the fiscal year ended December 31, 2021.
Revenue & Other Support:
Contributions $18,941,837
Other Support $7,072,076
Total Revenue & Other Support: $26,013,913
Program Expenditures:
Research $ 11,693,925
Scientific programs $9,253,814
Public policy $ 647,293
Total Program Expenditures: $21,595,032
Administration Expenditures: $2,174,307*
Fundraising Expenditures: $2,778,881*
End of Year Net Asset Balance: $69,486,118
*The LRA’s Supporting Services are covered by donations from its Board of Directors.
As of December 31, 2021, The Lupus Research Alliance has unrestricted financial reserves of approximately $59 million or about 2.2 times its most recent annual expenses, which totaled approximately $26.5 million. The majority of the $59 million is being held in a board designated endowment in order for the organization to have funds available for special research projects and is designated solely for lupus research.
Click on the following for more information:
-
- 2021 And 2020 Lupus Research Alliance Audited Financial Statement
- 2020 And 2019 Lupus Research Alliance Audited Financial Statement
- 2019 And 2018 Lupus Research Alliance Audited Financial Statement
- 2021 Lupus Research Alliance Annual Report
- 2020 Lupus Research Alliance Annual Report
- 2019 Lupus Research Alliance Annual Report
- 2017 and 2016 financials
- 2021 – 990
- 2020 – 990
- 2019 – 990
- IRS Determination Letter
- Whistleblower Policy
- Conflict of Interest Policy
- Pharmaceutical and Biotech Support of the Lupus Research Alliance
- LRA Corporate Relations Guidelines Executive Summary